ALKS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALKS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Alkermes's Net Income for the three months ended in Dec. 2024 was $147 Mil. Alkermes's Revenue for the three months ended in Dec. 2024 was $430 Mil. Therefore, Alkermes's net margin for the quarter that ended in Dec. 2024 was 34.07%.
The historical rank and industry rank for Alkermes's Net Margin % or its related term are showing as below:
The historical data trend for Alkermes's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
-10.67 | -4.10 | -14.24 | 21.39 | 23.57 |
Alkermes Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
29.88 | 10.51 | 22.89 | 24.43 | 34.07 |
For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Alkermes's Net Margin % distribution charts can be found below:
* The bar in red indicates where Alkermes's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Alkermes's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | 367.07 | / | 1557.632 | |
= | 23.57 % |
Alkermes's Net Margin for the quarter that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 146.503 | / | 429.986 | |
= | 34.07 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes (NAS:ALKS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Alkermes's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Craig C. Hopkinson | officer: SVP, Med Dev/Med Affairs, CMO | 852 WINTER STREET, WALTHAM MA 02451 |
Cato T Laurencin | director | C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800 |
Christian Todd Nichols | officer: SVP, Chief Commercial Officer | 852 WINTER STREET, WALTHAM MA 02451 |
Nancy Wysenski | director | 2200 SUNBURST STREET, CHATSWORTH CA 90401 |
Daglio David Angelo Jr. | director | ALKERMES, 852 WINTER STREET, WALTHAM MA 02451 |
Christopher I Wright | director | C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142 |
Michael J Landine | officer: SVP, Corp Dev., Alkermes, Inc. | 88 SIDNEY ST, CAMBRIDGE MA 021394136 |
Richard F Pops | director, officer: Director and CEO, Alkermes plc | 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121 |
Shane Cooke | officer: President, Alkermes plc | TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000 |
Blair Curtis Jackson | officer: EVP, Chief Operating Officer | 852 WINTER STREET, WALTHAM MA 02451 |
Snyderman Nancy Lynn Md | director | 37 PHEASANT HILL ROAD, PRINCETON NJ 08540 |
Emily Peterson Alva | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Iain Michael Brown | officer: VP, Finance & CAO | 14 ROYALSTON AVENUE, WINCHESTER MA 01890 |
Brian P Mckeon | director | IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092 |
David Joseph Gaffin | officer: SVP, CLO, Alkermes, Inc. | 852 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By GuruFocus News • 02-11-2025
By GuruFocus News • 02-12-2025
By GuruFocus News • 11-22-2024
By GuruFocus News • 10-25-2024
By GuruFocus News • 02-12-2025
By GuruFocus News • 02-12-2025
By GuruFocus News • 11-11-2024
By GuruFocus News • 11-05-2024
By GuruFocus News • 02-13-2025
By PRNewswire • 11-11-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.